PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.34%
EBIT growth above 1.5x CRVO's 3.03%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
30.35%
Operating income growth above 1.5x CRVO's 3.03%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
30.26%
Positive net income growth while CRVO is negative. John Neff might see a big relative performance advantage.
30.58%
EPS growth under 50% of CRVO's 100.00%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
33.88%
Diluted EPS growth under 50% of CRVO's 100.00%. Michael Burry would worry about an eroding competitive position or excessive dilution.
0.94%
Slight or no buybacks while CRVO is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
5.92%
Slight or no buyback while CRVO is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
10.50%
Positive OCF growth while CRVO is negative. John Neff would see this as a clear operational advantage vs. the competitor.
10.43%
Positive FCF growth while CRVO is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10668.67%
Negative 10Y OCF/share CAGR while CRVO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
79.98%
OCF/share CAGR of 79.98% while CRVO is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
60.25%
3Y OCF/share CAGR of 60.25% while CRVO is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
-3178.86%
Negative 10Y net income/share CAGR while CRVO is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
82.89%
Net income/share CAGR of 82.89% while CRVO is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
76.87%
3Y net income/share CAGR of 76.87% while CRVO is zero. Bruce Berkowitz sees if minor improvements can widen to a bigger advantage.
496.60%
Equity/share CAGR of 496.60% while CRVO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
159.22%
Equity/share CAGR of 159.22% while CRVO is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
-89.45%
Negative 3Y equity/share growth while CRVO is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.48%
Negative asset growth while CRVO invests at 48.86%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-43.72%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
14.13%
We have some new debt while CRVO reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
-30.15%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-30.87%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.